- Home
- / Perspectum Diagnostics
Perspectum Diagnostics
Total Funding
$46.7 M
Revenue
£8.5 M
FY, 2021
Perspectum Diagnostics Summary
Company Summary
- Overview
- Perspectum is a company that develops imaging technologies for the assessment of chronic diseases. Its MRI-based products include LiverMultiScan for liver assessment, MRCP+ for biliary system analysis, Hepatica for liver evaluation, and CoverScan MD for multi-organ imaging. The company serves clinicians and researchers in hepatology, metabolic diseases, oncology, and infectious diseases.
- Type
- Private
- Status
- Active
- Founded
- 2012
- HQ
- Oxford, GB | view all locations
- Website
- https://perspectum.com
- Cybersecurity rating
Table of Contents
Key People
Michael Brady, Co-Founder
Matthew Robson, Chief Technology Officer
Elizabeth Fagan, Non-Executive Director
Operating MetricsView all
Products
4
May, 2024
Client Types
4
May, 2024
Trademarks
22
May, 2024
LocationsView all
6 locations detected
Oxford, England HQ
United Kingdom
Gemini One, 5520 John Smith Drive
Cambridge, MA
United States
245 Main Street, Kendall Square
Dallas, TX
United States
600 North Pearl Street, Suite 1960, Plaza of The Americas
South San Francisco, CA
United States
400 Oyster Point Blvd, Suite 435
Lisbon, Lisboa
Portugal
Avenida Antonio Augusto de Aguiar, no 19, 4th Floor right, Room B
Singapore
Singapore
42 Tras Street, 03-01 and 03-03
Perspectum Diagnostics Financials
Summary Financials
- Revenue (FY, 2021)
- £8.5M
- Gross profit (FY, 2021)
- £6.1M
- Net income (FY, 2021)
- (£20.5M)
- Cash (FY, 2021)
- £14.7M
- EBIT (FY, 2021)
- (£23.6M)